An observational study in Non Small Cell Lung Cancer, Small Cell Lung Carcinoma and NUT Carcinoma, sponsored by Dana-Farber Cancer Institute. Recruiting at 4 sites in United States. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Dana-Farber Cancer Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Carcinoma, Non-Small-Cell Lung by Dana-Farber Cancer Institute — 4 open to participants now, 7 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Dana-Farber Cancer Institute.
Among the 20 studies in Carcinoma, Non-Small-Cell Lung by Dana-Farber Cancer Institute, this one is the only one that started in 2023, is the only observational one, and was the 18th registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →4 of the 20 studies in Carcinoma, Non-Small-Cell Lung by Dana-Farber Cancer Institute are open now, in 1 country. Recruiting first, the newest first:
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 15 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 1
First in 1998; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 160 across 1,151 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 30 across the 19 interventional studies, 500 across the 1 observational. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
Dana-Farber Cancer Institute is the lead sponsor of 836 studies on the registry; 121 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 78 (68%) have results posted.
4 of the studies in Carcinoma, Non-Small-Cell Lung by Dana-Farber Cancer Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07412041Dana-Farber Cancer InstitutePrecise Exercise Regimen for Cancer Care (PERCC): A Pilot Study | 2027-03-30 |
| NCT03392246Dana-Farber Cancer InstituteA Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer | 2027-06-30 |
| NCT05265429Dana-Farber Cancer InstituteBiology of Young Lung Cancer Study: The YOUNG LUNG Study | 2027-08-01 |
| NCT07938463Dana-Farber Cancer InstituteLorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies in Carcinoma, Non-Small-Cell Lung by Dana-Farber Cancer Institute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.
This research study looks to enroll as many people diagnosed with lung cancer at 45 years old or younger in order to:
Study procedures will include:
It is expected that about 500 people will take part in this research study. Participants will be in this study until it closes or the participant withdraws consent.
Adults age 45 or under at time of non-small lung cancer (NSCLC) or small cell lung cancer (SCLC) diagnosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tumor and saliva specimens from participants with non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) diagnosed at age 45 or younger
Genetic: Data and Specimen Collection
* Provide research team access to relevant medical records * Answer two (2) short questionnaires at time of consent * Provide up to 5 tubes (37 ml) of blood at or near the time of consent, and/or saliva sample * Consider consenting to other optional parts of the research such as: * Providing additional blood or tissue samples in the future (optional) * Providing permission for obtainment of stored tissue specimens from lung cancer surgeries or biopsies from the pathology departments where they have been stored (optional)
Repository of specimens and data
Prospective registry of young lung cancer specimens for exploratory tumor and germline genomics, transcriptomics/proteomics, and future biomarker study.
Time frame: 5 years or study closure
Number of patients with targetable somatic alterations in known oncogenic driver genes
Targetable alterations are defined as any somatic alteration in a driver oncogene for which a Food and Drug Administration-approved therapy exists, for which an off-label therapy exists, or for which a clinical trial exists (including but not limited to EGFR, KRAS, ALK, ROS1, RET, MET, BRAF, and TRK). Results will be summarized using descriptive statistics.
Time frame: 5 years or study closure
Number of patients with predicted oncogenic alterations in unknown driver genes
Unknown driver genes include genes not currently known to be driver oncogenes in lung cancer, and for which no directed treatment exists. Results will be summarized using descriptive statistics.
Time frame: 5 years or study closure
Number of patients with pathogenic or likely pathogenic germline alterations in known cancer predisposition genes
Pathogenic or likely pathogenic variants based on classification by the American College of Medical Genetics and Genomics (ACMG). Results will be summarized using descriptive statistics.
Time frame: 5 years or study closure
Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data can be shared no earlier than 1 year following the date of publication
Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
No publications or documents are linked to this record.
Started Jan 2023 (actual). Primary completion is estimated for Aug 2027, 55 months after the start.
Of 358 non-industry observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 55 months is close to that.
Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →
Dana-Farber Cancer Institute →